- Home
- MMA vs IXHL Comparison
MMA vs IXHL Comparison
Compare MMA & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMA
- IXHL
- Stock Information
- Founded
- MMA 2013
- IXHL 2001
- Country
- MMA Australia
- IXHL Australia
- Employees
- MMA N/A
- IXHL N/A
- Industry
- MMA
- IXHL
- Sector
- MMA
- IXHL
- Exchange
- MMA Nasdaq
- IXHL Nasdaq
- Market Cap
- MMA 38.9M
- IXHL 39.2M
- IPO Year
- MMA 2024
- IXHL N/A
- Fundamental
- Price
- MMA $1.97
- IXHL $2.34
- Analyst Decision
- MMA
- IXHL
- Analyst Count
- MMA 0
- IXHL 0
- Target Price
- MMA N/A
- IXHL N/A
- AVG Volume (30 Days)
- MMA 85.2K
- IXHL 39.3K
- Earning Date
- MMA 11-19-2024
- IXHL 09-30-2024
- Dividend Yield
- MMA N/A
- IXHL N/A
- EPS Growth
- MMA N/A
- IXHL N/A
- EPS
- MMA N/A
- IXHL N/A
- Revenue
- MMA $375,175.00
- IXHL $12,000.00
- Revenue This Year
- MMA N/A
- IXHL N/A
- Revenue Next Year
- MMA N/A
- IXHL N/A
- P/E Ratio
- MMA N/A
- IXHL N/A
- Revenue Growth
- MMA 45.19
- IXHL N/A
- 52 Week Low
- MMA $1.41
- IXHL $0.80
- 52 Week High
- MMA $5.25
- IXHL $12.68
- Technical
- Relative Strength Index (RSI)
- MMA N/A
- IXHL 50.20
- Support Level
- MMA N/A
- IXHL $2.22
- Resistance Level
- MMA N/A
- IXHL $3.12
- Average True Range (ATR)
- MMA 0.00
- IXHL 0.24
- MACD
- MMA 0.00
- IXHL 0.00
- Stochastic Oscillator
- MMA 0.00
- IXHL 15.22
About MMA Alta Global Group Limited
Alta Global Group Ltd is a technology company that is enabling the martial arts and combat sports industry to maximize the monetization opportunities available to the sector by increasing consumer participation in the sport and building upon existing community offerings within the sector. The Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.